Tagged with r&d

Pharma Digital health startups raised over USD six billion in equity financing in 2016, representing a five-year compound annual growth rate of 32 percent and the fledgling industry segment already boasts at least eight unicorns with a combined value exceeding USD 15 billion. Most interesting of all, however, is the constellation…

UK Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by 2022. However, despite possessing the innovators, the infrastructure and the coverage, the UK’s thriving vaccine industry risks being blown off…

UK Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and meet current health needs. Lundbeck is now focused on four key CNS areas: depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease.…

Spain Spanish biotech ALGENEX is using insect pupae to develop high-purity vaccines more quickly and at a lower cost than conventional production methods. Having secured further investment from outside of Spain, ALGENEX is now looking to produce its first vaccine for European regulators using insect-based production methods. We realised the huge…

UK Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as a homegrown British biotech with confidence. Its CEO Andrew Hotchkiss also shares some of the up-coming investigation programmes for Immunocore’s…

3D Bioprinting With the US FDA approval of a 3D bioprinted drug in 2016, the floodgates have been opened for a new wave of innovative, personalized and customizable printed medicine.   Printing tailored medicine could simplify our supply chain dramatically. Martin Wallace, GSK   3D Bioprinting on the Rise Many healthcare and…

Malta UMANA T1 – a patient monitoring ecosystem that uses tattoo sensor technology to measure and record heart rate and other physiological parameters – stands as one of the most innovative technologies ever developed in Malta and could herald a shift in the island nation’s innovation landscape. “The operating environment [in…

Spain Jose Manuel Rigueiro, general manager of the Spanish affiliate of Actelion, discusses the lack of trust between health authorities and the industry and the challenges of launching new orphan drugs in such a fragmented healthcare system. He highlights the successful launch of Uptravi® and his commitment to avoid business disruption…

Portugal Nelson Pires provides an insightful update on Portugual’s pharmaceutical market evolution as well as Jaba Recordati’s ambitious Portuguese affiliate. Pires shares that diversification is one technique of navigating the market, introduces their expansion into a new therapeutic area, and explains the affiliate’s new venture into Nigeria. Would you be able…

UK Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug discovery profile post-Brexit.  Could you please start by introducing the MDC? “We believe that the future is going to be…

Pharma While the automotive and electronics industries, among others, have been relatively fast in adopting robotics, pharma has been lagging behind. However, as the technology available becomes more advanced, flexible and affordable, robotics now stands as a pivotal element to helping pharmaceutical companies reduce costs and increase efficiency, notably in the…

Europe The top spenders on pharma R&D in Europe for 2015 were Switzerland – which spent over EUR 6.5 billion – followed by Germany – which spent EUR 6.2 billion – and the UK – which spent EUR 5.8 billion.